UMB Bank n.a. Has $37,000 Holdings in Insulet Co. (NASDAQ:PODD)

UMB Bank n.a. increased its stake in Insulet Co. (NASDAQ:PODD) by 81.0% in the second quarter, Holdings Channel.com reports. The firm owned 181 shares of the medical instruments supplier’s stock after purchasing an additional 81 shares during the quarter. UMB Bank n.a.’s holdings in Insulet were worth $37,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Panagora Asset Management Inc. boosted its stake in shares of Insulet by 323.9% during the 2nd quarter. Panagora Asset Management Inc. now owns 21,367 shares of the medical instruments supplier’s stock worth $4,312,000 after buying an additional 16,326 shares during the last quarter. Arkadios Wealth Advisors acquired a new position in shares of Insulet during the 2nd quarter worth about $201,000. HB Wealth Management LLC acquired a new position in shares of Insulet during the 2nd quarter worth about $273,000. Dearborn Partners LLC acquired a new position in shares of Insulet during the 2nd quarter worth about $202,000. Finally, State of Michigan Retirement System boosted its stake in shares of Insulet by 0.5% during the 2nd quarter. State of Michigan Retirement System now owns 19,200 shares of the medical instruments supplier’s stock worth $3,875,000 after buying an additional 100 shares during the last quarter.

Insiders Place Their Bets

In other Insulet news, SVP Mark N. Field sold 2,131 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.43, for a total transaction of $405,806.33. Following the transaction, the senior vice president now owns 14,375 shares in the company, valued at approximately $2,737,431.25. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Timothy J. Scannell sold 7,000 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the sale, the director now owns 35,586 shares in the company, valued at approximately $6,779,488.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mark N. Field sold 2,131 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the sale, the senior vice president now owns 14,375 shares in the company, valued at approximately $2,737,431.25. The disclosure for this sale can be found here. Insiders have sold a total of 10,631 shares of company stock worth $2,039,316 in the last quarter. Corporate insiders own 0.47% of the company’s stock.

Insulet Stock Down 1.2 %

Insulet stock opened at $202.77 on Friday. The stock has a market cap of $14.20 billion, a P/E ratio of 61.45, a P/E/G ratio of 3.62 and a beta of 1.16. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $223.56. The company’s 50-day moving average price is $195.59 and its two-hundred day moving average price is $183.57.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. During the same quarter in the previous year, the company earned $0.38 EPS. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. As a group, analysts expect that Insulet Co. will post 3.04 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. UBS Group increased their price objective on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. OTR Global reaffirmed a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Redburn Atlantic began coverage on shares of Insulet in a report on Thursday, May 30th. They issued a “buy” rating and a $235.00 target price on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $234.00 target price on shares of Insulet in a report on Tuesday, July 23rd. Finally, Raymond James dropped their target price on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $225.29.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.